Barclays analyst Peter Lawson lowered the firm’s price target on Biomea Fusion to $30 from $60 and keeps an Overweight rating on the shares post the Q3 report. The analyst de-risked the model and the firm’s focus remains on data updates for covalent menin inhibitor BMF-219 in Q4.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMEA:
- Biomea Fusion reports Q3 EPS (80c), consensus (82c)
- Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
- Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
- Biomea Fusion announces first patient dosed in COVALENT-103 trial
- JPMorgan biotech analysts hold an analyst/industry conference call
